Management of Idiopathic Pulmonary Fibrosis

Margaret L Salisbury; Marlies S Wijsenbeek

doi:10.1016/j.ccm.2021.03.004

Management of Idiopathic Pulmonary Fibrosis

Clin Chest Med. 2021 Jun;42(2):275-285. doi: 10.1016/j.ccm.2021.03.004.

Authors

Margaret L Salisbury¹, Marlies S Wijsenbeek²

Affiliations

¹ Department of Medicine, Division of Allergy, Pulmonary and Critical Care, Vanderbilt University Medical Center, 1161 21st Avenue South, T-1209A Medical Center North, Nashville, TN 37232, USA. Electronic address: [email protected].
² Department of Respiratory Medicine, Centre for Interstitial Lung Diseases and Sarcoidosis, Erasmus Medical Center, University Medical Centre Rotterdam, Dr. Molewaterplein 40, Rotterdam 3015, GD, the Netherlands.

PMID: 34024403
DOI: 10.1016/j.ccm.2021.03.004

Abstract

Progress in the past 2 decades has led to widespread use of 2 medications to slow loss of lung function in patients with pulmonary fibrosis. Treatment of individual patients with currently available pharmacotherapies can be limited by side effects, and neither drug has a consistent effect on patient symptoms or function. Several promising new pharmacotherapies are under development. Comprehensive management of pulmonary fibrosis hinges on shared decision making. Patient and caregiver education, and early identification and management of symptoms and comorbidities, can help improve quality of life.

Keywords: Idiopathic pulmonary fibrosis; Palliative care; Pharmacotherapy.

Publication types

Review

MeSH terms

Comorbidity
Humans
Idiopathic Pulmonary Fibrosis / diagnosis
Idiopathic Pulmonary Fibrosis / drug therapy*
Idiopathic Pulmonary Fibrosis / epidemiology
Idiopathic Pulmonary Fibrosis / physiopathology
Quality of Life